217 related articles for article (PubMed ID: 35918309)
1. Spatiotemporal control of engineered bacteria to express interferon-γ by focused ultrasound for tumor immunotherapy.
Chen Y; Du M; Yuan Z; Chen Z; Yan F
Nat Commun; 2022 Aug; 13(1):4468. PubMed ID: 35918309
[TBL] [Abstract][Full Text] [Related]
2. Ultrasound-visible engineered bacteria for tumor chemo-immunotherapy.
Yang Y; Wang Y; Zeng F; Chen Y; Chen Z; Yan F
Cell Rep Med; 2024 May; 5(5):101512. PubMed ID: 38640931
[TBL] [Abstract][Full Text] [Related]
3. Ultrasound-controllable engineered bacteria for cancer immunotherapy.
Abedi MH; Yao MS; Mittelstein DR; Bar-Zion A; Swift MB; Lee-Gosselin A; Barturen-Larrea P; Buss MT; Shapiro MG
Nat Commun; 2022 Mar; 13(1):1585. PubMed ID: 35332124
[TBL] [Abstract][Full Text] [Related]
4. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
5. Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines.
Clary BM; Coveney EC; Blazer DG; Philip R; Lyerly HK
Surgery; 1996 Aug; 120(2):174-81. PubMed ID: 8751580
[TBL] [Abstract][Full Text] [Related]
6. Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors.
Knopf P; Stowbur D; Hoffmann SHL; Hermann N; Maurer A; Bucher V; Poxleitner M; Tako B; Sonanini D; Krishnamachary B; Sinharay S; Fehrenbacher B; Gonzalez-Menendez I; Reckmann F; Bomze D; Flatz L; Kramer D; Schaller M; Forchhammer S; Bhujwalla ZM; Quintanilla-Martinez L; Schulze-Osthoff K; Pagel MD; Fransen MF; Röcken M; Martins AF; Pichler BJ; Ghoreschi K; Kneilling M
Mol Cancer; 2023 Dec; 22(1):207. PubMed ID: 38102680
[TBL] [Abstract][Full Text] [Related]
7. Near-Infrared-Light Remote-Controlled Activation of Cancer Immunotherapy Using Photothermal Conjugated Polymer Nanoparticles.
Fu X; Huang Y; Zhao H; Zhang E; Shen Q; Di Y; Lv F; Liu L; Wang S
Adv Mater; 2021 Aug; 33(34):e2102570. PubMed ID: 34278634
[TBL] [Abstract][Full Text] [Related]
8. Bacteria-Based Cancer Immunotherapy.
Huang X; Pan J; Xu F; Shao B; Wang Y; Guo X; Zhou S
Adv Sci (Weinh); 2021 Apr; 8(7):2003572. PubMed ID: 33854892
[TBL] [Abstract][Full Text] [Related]
9. New strategies for active immunotherapy with genetically engineered tumor cells.
Pardoll D
Curr Opin Immunol; 1992 Oct; 4(5):619-23. PubMed ID: 1418729
[TBL] [Abstract][Full Text] [Related]
10. KERS-Inspired Nanostructured Mineral Coatings Boost IFN-γ mRNA Therapeutic Index for Antitumor Immunotherapy.
Shao Z; Chen L; Zhang Z; Wu Y; Mou H; Jin X; Teng W; Wang F; Yang Y; Zhou H; Xue Y; Eloy Y; Yao M; Zhao S; Cui W; Yu X; Ye Z
Adv Mater; 2023 Dec; 35(51):e2304296. PubMed ID: 37587307
[TBL] [Abstract][Full Text] [Related]
11. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
12. Pan-cancer analysis of IFN-γ with possible immunotherapeutic significance: a verification of single-cell sequencing and bulk omics research.
Wei X; Ruan H; Zhang Y; Qin T; Zhang Y; Qin Y; Li W
Front Immunol; 2023; 14():1202150. PubMed ID: 37646041
[TBL] [Abstract][Full Text] [Related]
13. Regulation of tumor growth by IFN-gamma in cancer immunotherapy.
Beatty GL; Paterson Y
Immunol Res; 2001; 24(2):201-10. PubMed ID: 11594457
[TBL] [Abstract][Full Text] [Related]
14. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy.
Han J; Wu M; Liu Z
Front Immunol; 2023; 14():1190333. PubMed ID: 37275859
[TBL] [Abstract][Full Text] [Related]
16. The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity.
Seo SH; Kim KS; Park SH; Suh YS; Kim SJ; Jeun SS; Sung YC
Gene Ther; 2011 May; 18(5):488-95. PubMed ID: 21228885
[TBL] [Abstract][Full Text] [Related]
17. Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment.
Lin W; Luo Y; Wu J; Zhang H; Jin G; Guo C; Zhou H; Liang H; Xu X
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935565
[TBL] [Abstract][Full Text] [Related]
18. [A novel experimental approach to immunotherapy against malignant brain tumor with the mouse IFN-gamma gene transfer].
Nishihara K
Nihon Geka Hokan; 1989 Jan; 58(1):18-42. PubMed ID: 2508589
[TBL] [Abstract][Full Text] [Related]
19. Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies.
Mizokami MM; Hu P; Khawli LA; Li J; Epstein AL
Hybrid Hybridomics; 2003 Aug; 22(4):197-207. PubMed ID: 14511565
[TBL] [Abstract][Full Text] [Related]
20. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
